Project Grant HT94252510439
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$673K
Federal Agency
Defense Health Agency
Awardee
Brown University (E3FDXZ6TBHW3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Providence, RI 02912, USA
Similar Awards
This federal Project Grant award of $533,875.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports Brown University's research to develop ultrasensitive stool tests for Line-1 ORF1P detection to aid in gastric cancer diagnosis. The award, effective June 1, 2025 through May 31, 2027, will enable Brown University's innovative research to advance early detection capabilities for this form of cancer. The Military Medical Research and Development...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The federal Project Grant award of $957,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Brown University. The grant, titled "OPTIMIZING CLOPIDOGREL TO TREAT ALS," aims to support advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The award will fund research focused on optimizing the use of the drug clopidogrel to treat amyotrophic lateral...
The Defense Health Agency awarded $145,570 to Rice University under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of September 30, 2021 through September 29, 2023. The project aims to develop mutation-targeted immunotherapy for the treatment of rare cancers. Through this funding, Rice University researchers will investigate medical solutions for cancer on the battlefield and for the general public. The grant supports basic, applied, and advanced...
This federal Project Grant award of $2,542,500.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research aimed at therapeutically targeting the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse, as well as preclinical models of lung metastases. The award was granted to the Weill Medical College of Cornell University, a prestigious academic medical institution, with a performance...
This $1,131,495 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at William Marsh Rice University to develop a bone-targeting E-cadherin antibody nanogel to eliminate bone metastasis. The 3-year award, running from April 1, 2025 to March 31, 2028, will fund innovative biomedical research to transform healthcare for military service members, veterans, and the broader public. This effort...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The U.S. Department of Defense's Defense Health Agency awarded a $1,107,000 Project Grant to Rhode Island Hospital, a division of Lifespan Corp, to support the "ENGINEERED NEUTROPHILS FOR INTRATUMORAL DELIVERY AND TARGETING" research project. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, will be used to conduct basic, translational, and clinical research aimed at developing new treatments and improving patient care related to cancer,...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...